| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 12/19/2012 | CN102834114A Fibronectin type iii domain-based multimeric scaffolds |
| 12/19/2012 | CN102834113A Pharmaceutical composition for treating and/or preventing cancer |
| 12/19/2012 | CN102834112A Polysaccharide particle vaccines |
| 12/19/2012 | CN102834106A Methods for producing an immune response to tuberculosis |
| 12/19/2012 | CN102827864A Recombinant bacillus subtilis CoxA16-VP1 expression vector as well as preparation method and application thereof |
| 12/19/2012 | CN102827857A Plasmid vector of L1 protein coding gene containing human papilloma virus 16 (HPV16) and construction method thereof |
| 12/19/2012 | CN102827846A Preparation method and application of recombination coxsackie virus B3-type virus-like particles |
| 12/19/2012 | CN102827813A Anti-human CD133 monoclonal antibody and preparation method and applications thereof |
| 12/19/2012 | CN102827289A Porcine circovirus type 2 Cap protein and thymosin alpha1 fusion protein and application |
| 12/19/2012 | CN102827287A Compositions and methods for diagnosing and treating cancer |
| 12/19/2012 | CN102827282A Human resistant Trop-2 genetically engineered antibody immunoglobulin G (IgG) and application thereof |
| 12/19/2012 | CN102827280A Anti-IL-13 antibodies and use thereof |
| 12/19/2012 | CN102827259A Porcine circovirus type 2 (PCV2) Cap protein gene and application thereof |
| 12/19/2012 | CN102824645A Gosling plague egg yolk antibody freeze-drying protective additive |
| 12/19/2012 | CN102824637A Application of TRPC5 as drug target in reversing multi-drug resistance |
| 12/19/2012 | CN102824635A Application of chitosan as adjuvant in preparation of influenza virus attenuated live vaccine |
| 12/19/2012 | CN102824634A Recombined Swinepox virus carrier vaccine capable of expressing porcine circovirus 2-type Cap protein and preparation method thereof |
| 12/19/2012 | CN102824633A Tetravalent dengue virus subunit vaccine, its preparation method and application thereof |
| 12/19/2012 | CN102824632A Polysaccharide conjugate vaccine of vibrio cholera group O1, preparation method and application thereof |
| 12/19/2012 | CN102824631A Preparation and application of strptococcus iniae attenuated vaccine |
| 12/19/2012 | CN102443572B Method for purifying detoxified pertussis vaccine antigen solution |
| 12/19/2012 | CN102220293B Dog flu recombinant virus as well as preparation method and application thereof |
| 12/19/2012 | CN102188449B Preparation method of high-immune whole-egg powder for resisting piglet diarrhea |
| 12/19/2012 | CN102178950B Subunit vaccine immunologic adjuvant and application thereof |
| 12/19/2012 | CN102040658B Schistosoma japonica polypeptide with immunogenicity and application thereof |
| 12/19/2012 | CN101974535B Preparation and application of novel anti-ErbB2 humanized antibody MIL12 |
| 12/19/2012 | CN101972476B DNA vaccine adjuvant using Micro RNA-155 and construction method thereof |
| 12/19/2012 | CN101905021B Trigeminal live vaccine of canine distemper viruses, canine parvoviruses and Type I canine adenoviruses and preparation method thereof |
| 12/19/2012 | CN101437540B Melanocortin receptor binding mimetibodies, compositions, methods and uses |
| 12/19/2012 | CN101001874B Poly-n-acetyl glucosamine (PNAG/DPNAG)-binding peptides and methods of use thereof |
| 12/18/2012 | US8334283 Compositions and methods for treating, reducing, ameliorating, or preventing infections |
| 12/18/2012 | US8334146 Method of altering the binding specificity of plasma proteins by oxidation-reduction reactions |
| 12/18/2012 | US8334114 Lactoferrin cleavage of neisserial proteins |
| 12/18/2012 | US8334102 Human CD28 specific monoclonal antibodies for antigen-nonspecific activation of T-lymphocytes |
| 12/18/2012 | US8334000 Anti-angiogenic extracts from pomegranate |
| 12/18/2012 | US8333996 Adjust particle size; induce immunology response; vaccines |
| 12/18/2012 | US8333995 Protein microspheres having injectable properties at high concentrations |
| 12/18/2012 | US8333980 Methods of modulating an immune response using immunostimulatory sequences and compositions for use therein |
| 12/18/2012 | US8333978 Poly TLR antagonist |
| 12/18/2012 | US8333977 Inactivated staphylococcal whole-cell vaccine |
| 12/18/2012 | US8333976 Processes for inhibiting development of allergic disease |
| 12/18/2012 | US8333975 Influenza hemagglutinin and neuraminidase variants |
| 12/18/2012 | US8333973 Targeting recombinant therapeutics to circulating red blood cells |
| 12/18/2012 | US8333972 Unconventional antigen translated by a novel internal ribosome entry site elicits antitumor humoral immune reactions |
| 12/18/2012 | US8333971 Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments |
| 12/18/2012 | US8333970 Methods of monitoring the efficacy of anti-CD40 antibodies in treating a subject having an inflammatory or autoimmune disease |
| 12/18/2012 | US8333969 Use of immunesuppressant receptor |
| 12/18/2012 | US8333968 Methods of inhibiting inflammation with antagonists to IL-17A, IL-17F, and IL-23P19 |
| 12/18/2012 | US8333967 Anti-Aβ oligomer humanized antibody |
| 12/18/2012 | US8333966 CD37 immunotherapeutics and uses thereof |
| 12/18/2012 | US8333965 Anti-inteferon alpha monoclonal antibodies and methods for use |
| 12/18/2012 | US8333964 ErbB antagonists for pain therapy |
| 12/18/2012 | US8333963 Method of inhibiting osteoclast activity |
| 12/18/2012 | US8333953 Methods of delivery of exogenous proteins to the cytosol and uses thereof |
| 12/18/2012 | CA2754102C Monoclonal antibodies and compositions comprising such useful for inhibition of .alpha.v.beta.5 mediated angiogenesis |
| 12/18/2012 | CA2589421C Erbb3 antibodies |
| 12/18/2012 | CA2579861C Formulation of pertuzumab in a histidine-acetate buffer |
| 12/18/2012 | CA2524002C Sars-related proteins |
| 12/18/2012 | CA2489275C Antigenic targets of autoimmune sensorineural hearing loss (aisnhl) and development of tests for diagnosis and management of aisnhl |
| 12/18/2012 | CA2472163C Psoriasin expression by breast epithelial cells |
| 12/18/2012 | CA2466034C Stable aqueous pharmaceutical formulations of daclizumab antibodies |
| 12/18/2012 | CA2460468C Novel polypeptide, dna thereof and use of the same |
| 12/18/2012 | CA2445537C Antigen targeting |
| 12/18/2012 | CA2436057C A method for identification, isolation and production of antigens to a specific pathogen |
| 12/18/2012 | CA2407895C Use of il-18 inhibitors for the treatment and/or prevention of atherosclerosis |
| 12/18/2012 | CA2398064C 84p2a9: a prostate and testis specific protein highly expressed in prostate cancer |
| 12/18/2012 | CA2385122C Mutated anthrax toxin protective antigen proteins that specifically target cells containing high amounts of cell-surface metalloproteinases or plasminogen activator receptors |
| 12/18/2012 | CA2375269C A method of prophylaxis and treatment and agents useful for same |
| 12/18/2012 | CA2363486C Compositions and methods for effecting the levels of high density lipoprotein (hdl) cholesterol and apolipoprotein ai, very low density lipoprotein (vldl) cholesterol and low density lipoprotein (ldl) cholesterol |
| 12/13/2012 | WO2012170997A1 Paramyxovirus immunogens and related materials and methods |
| 12/13/2012 | WO2012170979A1 Human homeobox gene ventx and macrophage terminal differentiation and activation, compositions and methods thereof |
| 12/13/2012 | WO2012170929A2 Monoclonal antibody and antigens for diagnosing and treating lung disease and injury |
| 12/13/2012 | WO2012170814A1 Norovirus immunogens and related materials and methods |
| 12/13/2012 | WO2012170807A2 Anti-pseudomonas psl binding molecules and uses thereof |
| 12/13/2012 | WO2012170785A1 Anti-cd22 antigen binding molecules to treat lung cancer and prostate cancer |
| 12/13/2012 | WO2012170776A2 Methods of determining a patient's prognosis for recurrence of prostate cancer and/or determining a course of treatment for prostate cancer following a radical prostatectomy |
| 12/13/2012 | WO2012170753A2 Bovine vaccines and methods |
| 12/13/2012 | WO2012170742A2 Treatment and prevention of cancer with hmgb1 antagonists |
| 12/13/2012 | WO2012170607A2 Use of pcsk9 antagonists |
| 12/13/2012 | WO2012170513A2 He4 based therapy for malignant disease |
| 12/13/2012 | WO2012170438A2 HUMAN ANTIGEN BINDING PROTEINS THAT BIND TO A COMPLEX COMPRISING β-KLOTHO AND AN FGF RECEPTOR |
| 12/13/2012 | WO2012170356A1 Compositions and methods related to p6 of haemophilus influenzae |
| 12/13/2012 | WO2012170125A2 Algal produced malarial transmission blocking vaccines |
| 12/13/2012 | WO2012170097A2 Compositions and methods for inducing immune responses against bacteria in the genus staphylococcus |
| 12/13/2012 | WO2012170084A1 Composition and method for treating lung disease and mucous cell metaplasia |
| 12/13/2012 | WO2012170072A1 Engineered antibody-tnfsf member ligand fusion molecules |
| 12/13/2012 | WO2012169911A1 Peptides, constructs and uses therefor |
| 12/13/2012 | WO2012169741A2 Fcεri-specific human antibody and composition comprising same for treating or diagnosing allergic diseases |
| 12/13/2012 | WO2012169735A2 Complex comprising water-soluble fragments of fcεri and composition comprising same for treating allergic diseases mediated by ige |
| 12/13/2012 | WO2012169200A1 Sema5b peptides and vaccines including the same |
| 12/13/2012 | WO2012168818A1 Infectious clones of torque teno virus |
| 12/13/2012 | WO2012168491A1 Pharmaceutical formulations of pcsk9 antagonists |
| 12/13/2012 | WO2012168487A1 Peptide carrier fusion proteins as allergy vaccines |
| 12/13/2012 | WO2012168486A1 Cetp fragments |
| 12/13/2012 | WO2012168480A1 Agents and methods for producing hiv-capsid derived non-infectious adjuvants |
| 12/13/2012 | WO2012168259A1 Protein tyrosine phosphatase, non-receptor type 11 (ptpn11) and triple-negative breast cancer |
| 12/13/2012 | WO2012168199A1 Therapeutic antibodies |
| 12/13/2012 | WO2012167382A1 Compositions and methods for glioblastoma treatment |
| 12/13/2012 | WO2012167346A1 Anti-ricin antibodies and uses thereof |
| 12/13/2012 | WO2012167309A1 Macromolecules |